Gabapentin Should NOT Be Routinely Used for Tinnitus
Clinicians should not routinely recommend gabapentin (an anticonvulsant) for treating persistent, bothersome tinnitus. 1
The Evidence Against Gabapentin
The American Academy of Otolaryngology-Head and Neck Surgery 2014 clinical practice guideline explicitly recommends against the routine use of anticonvulsants (including gabapentin) for primary tinnitus treatment. This recommendation is based on:
- Grade B evidence from systematic reviews and RCTs with methodological concerns
- A preponderance of benefit in avoiding these medications rather than using them
- Known harms, costs, and potential for medications to worsen tinnitus 1
The guideline emphasizes avoiding unproven therapy, side effects/adverse events (including paradoxically worsening tinnitus), false hope, and unnecessary expense 1.
Research Evidence Shows Mixed and Weak Results
While some studies suggest potential benefit, the overall evidence is insufficient:
- A 2022 systematic review concluded there is insufficient evidence to recommend gabapentin for tinnitus patients 2
- The largest rigorous trial (135 patients) found gabapentin no more effective than placebo (Tinnitus Handicap Inventory score change: 11.3 vs 11.0, p=0.91) 3
- A 2011 RCT found no significant difference between gabapentin and placebo overall (p=0.85 for severity, p=0.12 for loudness) 4
The Exception That Proves the Rule
One subgroup analysis suggested patients with concomitant hypertension, diabetes, and/or dyslipidemia may respond better to gabapentin (p=0.01) 4. However, this finding requires validation and doesn't justify routine use.
A 2017 study in acoustic trauma patients showed benefit 5, but this represents a specific etiology rather than primary idiopathic tinnitus—the focus of guideline recommendations.
What SHOULD Be Recommended Instead
The guideline provides a clear hierarchy of evidence-based interventions:
First-Line Approaches:
- Cognitive-behavioral therapy (CBT) - should be recommended (based on RCTs with preponderance of benefit) 1
- Hearing aid evaluation for patients with hearing loss - should be recommended 1
- Education and counseling about management strategies 1
- Sound therapy - may be recommended 1
What to Avoid:
- Antidepressants, anticonvulsants, anxiolytics, or intratympanic medications should NOT be routinely recommended 1
- Dietary supplements (Ginkgo biloba, melatonin, zinc) should NOT be recommended 1
Important Caveats
The FDA has NOT approved gabapentin for tinnitus. The drug label only covers epilepsy and postherpetic neuralgia 6. Using gabapentin for tinnitus is off-label and lacks regulatory support.
Side effects matter. Gabapentin carries risks including myoclonus, ataxia, respiratory depression, encephalopathy, peripheral edema, suicidal ideation, and other atypical effects 7. These risks must be weighed against the lack of proven benefit.
The placebo effect is substantial. Multiple studies show significant improvement in control groups, with one study noting the placebo effect in tinnitus relief is "remarkable" 5. This makes interpreting positive results challenging.
Clinical Bottom Line
Do not prescribe gabapentin routinely for tinnitus. Instead, focus on CBT, hearing aids (if hearing loss present), education, and sound therapy—interventions with stronger evidence and guideline support. The potential harms and costs of gabapentin outweigh its unproven benefits for most tinnitus patients.